Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Varicella Vaccination of Children With Leukemia Without Interruption of Maintenance Therapy: A Danish Experience

Research output: Contribution to journalJournal articleResearchpeer-review

  1. LISTERIA MENINGITIS IN DANISH CHILDREN 2000-2017: A Rare Event Even in a Country With High Rates of Invasive Listeriosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pediatric Candidemia Epidemiology and Morbidities: A Nationwide Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Streptococcal Infections and Exacerbations in PANDAS: A Systematic Review and Meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Polygenic risk score-analysis of thromboembolism in patients with acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Management of Asparaginase Toxicity in AYAs with ALL

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Smartphone App to Self-Monitor Nausea During Pediatric Chemotherapy Treatment: User-Centered Design Process

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Varicella-zoster virus (VZV) can be fatal or cause severe complications in children with acute lymphoblastic leukemia (ALL). This analysis set out to investigate the morbidity and mortality of VZV vaccination without interruption of maintenance therapy in children with ALL.

METHODS: Files of 73 seronegative children with ALL were examined for data regarding VZV vaccination and infection, and long-term seroconversion was measured. Criteria before VZV vaccination were (1) seronegative, (2) in complete remission, (3) age ≥ 1.0 year, (4) lymphocyte count ≥ 0.6 × 10/L at time of vaccination and (5) receiving maintenance therapy.

RESULTS: Forty-five children were vaccinated. No child died or experienced serious adverse events due to VZV vaccination. Nine children developed late chickenpox despite vaccination. Long-term protection was found in 86% of children not receiving acyclovir and 78% of the entire population. Long-term seroconversion was found in 52% of the children. There were no severe cases of varicella infection. Acyclovir prophylaxis postvaccination was associated with an increased risk of late chickenpox [hazard ratio = 5.40 (1.43, 20.41), P = 0.01]. In contrast, a vaccine-induced rash reduced the risk of late chickenpox [hazard ratio = 0.08 (0.01, 0.66), P = 0.02]. No child had interruption of maintenance therapy at the time of vaccination, but 33% experienced discontinuation of therapy due to vaccine-induced rash. Dexamethasone was associated with an increased risk of vaccine-induced rash [hazard ratio = 2.9 (1.21, 6.90), P = 0.02].

CONCLUSIONS: This analysis indicates that VZV vaccination is feasible and justified in seronegative children with ALL, in countries where VZV vaccination is not part of the national vaccination program.

Original languageEnglish
JournalThe Pediatric infectious disease journal
Volume35
Issue number11
Pages (from-to)e348-e352
ISSN0891-3668
DOIs
Publication statusPublished - Nov 2016

ID: 49873149